Get the Stockscreener App
2.90
1.05%
0.03
After Hours:
2.89
-0.010
-0.34%
Immunitybio Inc stock is traded at $2.90, with a volume of 4.25M.
It is up +1.05% in the last 24 hours and down -12.65% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.87
Open:
$2.84
24h Volume:
4.25M
Relative Volume:
0.68
Market Cap:
$2.47B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.9897
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-3.01%
1M Performance:
-12.65%
6M Performance:
-18.99%
1Y Performance:
-42.91%
1-Day Range:
$2.835
$3.03
1-Week Range:
$2.73
$3.065
52-Week Range:
$2.28
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.90 | 2.47B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Recombinant BCG Vaccine Becomes Available in the U.S. - Precision Vaccinations
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching - BioSpace
ImmunityBio Partner US Urology Begins Administering rBCG to Address Tice BCG Shortage - Marketscreener.com
ImmunityBio, Inc. (IBRX): Among the Stocks Under $10 With High Upside Potential - Insider Monkey
ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday - Defense World
SBI Securities Co. Ltd. Buys New Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Q1 Earnings Forecast for ImmunityBio Issued By HC Wainwright - Defense World
Private Advisor Group LLC Cuts Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
HC Wainwright Begins Coverage on ImmunityBio (NASDAQ:IBRX) - Defense World
H.C. Wainwright sets $8 target for ImmunityBio stock, rates Buy By Investing.com - Investing.com South Africa
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - Benzinga
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
H.C. Wainwright sets $8 target for ImmunityBio stock, rates Buy - Investing.com
HC Wainwright Initiates Coverage on ImmunityBio With Buy Rating, $8 Price Target -March 06, 2025 at 07:26 am EST - Marketscreener.com
HC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation - Nasdaq
H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating - TradingView
Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - Simply Wall St
New York State Common Retirement Fund Grows Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
ImmunityBio (NASDAQ:IBRX) Trading Up 6.8% Following Strong Earnings - Defense World
Why ImmunityBio Inc. (IBRX) Crashed on Monday - MSN
ImmunityBio Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
ImmunityBio: Q4 Earnings Snapshot - Barchart
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Bought by Handelsbanken Fonder AB - Defense World
ImmunityBio’s Sales Surge Amid Strategic Advances - TipRanks
ImmunityBio stock rises on Q4 earnings beat, revenue growth - Investing.com India
Why ImmunityBio, Inc. (IBRX) Soared on Friday - MSN
ImmunityBio stock rises on Q4 earnings beat, revenue growth By Investing.com - Investing.com South Africa
Immunitybio Inc earnings beat by $0.08, revenue topped estimates - Investing.com South Africa
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates - MSN
ImmunityBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 - BioSpace
ImmunityBio, Inc. SEC 10-K Report - TradingView
Earnings Flash (IBRX) ImmunityBio Posts Q4 Net Loss $-0.09 a Share, vs. FactSet Est of $-0.20 Loss - Marketscreener.com
Earnings Flash (IBRX) IMMUNITYBIO INC. Posts Q4 Revenue $7.6M, vs. FactSet Est of $9.6M - Marketscreener.com
ImmunityBio reports Q4 EPS (9c), consensus (13c) - TipRanks
FDA RMAT designation for ImmunityBio’s Anktiva - The Pharma Letter
ImmunityBio (NASDAQ:IBRX) Shares Gap Up – Here’s Why - Defense World
ImmunityBio stock climbs 10% on FDA RMAT designation - MSN
Wall Street Optimism Spills Over to These 10 Stocks on Friday - Insider Monkey
ImmunityBio, Inc. Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-Of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancr - Marketscreener.com
ImmunityBio Shares Surge Amid FDA Collaboration - TipRanks
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
ImmunityBio receives FDA RMAT designation for Anktiva - TipRanks
IMMUNITYBIO, INC. (NASDAQ: IBRX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ImmunityBio, Inc. - ACCESS Newswire
Immunitybio Receives FDA Rmat Designation For Anktiva® And Car-Nk -February 27, 2025 at 07:11 pm EST - Marketscreener.com
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreat - Yahoo Finance UK
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):